HomeCompareVRISX vs ABBV

VRISX vs ABBV: Dividend Comparison 2026

VRISX yields 4.31% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VRISX wins by $2705.01M in total portfolio value
10 years
VRISX
VRISX
● Live price
4.31%
Share price
$18.79
Annual div
$0.81
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2705.12M
Annual income
$2,589,722,437.35
Full VRISX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VRISX vs ABBV

📍 VRISX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVRISXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VRISX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VRISX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VRISX
Annual income on $10K today (after 15% tax)
$366.46/yr
After 10yr DRIP, annual income (after tax)
$2,201,264,071.75/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, VRISX beats the other by $2,201,243,015.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VRISX + ABBV for your $10,000?

VRISX: 50%ABBV: 50%
100% ABBV50/50100% VRISX
Portfolio after 10yr
$1352.61M
Annual income
$1,294,873,604.55/yr
Blended yield
95.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VRISX
No analyst data
Altman Z
0.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VRISX buys
0
ABBV buys
0
No recent congressional trades found for VRISX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVRISXABBV
Forward yield4.31%3.06%
Annual dividend / share$0.81$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$2705.12M$102.3K
Annual income after 10y$2,589,722,437.35$24,771.77
Total dividends collected$2696.92M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VRISX vs ABBV ($10,000, DRIP)

YearVRISX PortfolioVRISX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,562$862.26$11,550$430.00+$12.00VRISX
2$14,235$1,863.48$13,472$627.96+$763.00VRISX
3$19,520$4,288.34$15,906$926.08+$3.6KVRISX
4$31,878$10,991.39$19,071$1,382.55+$12.8KVRISX
5$67,660$33,551.20$23,302$2,095.81+$44.4KVRISX
6$205,504$133,107.21$29,150$3,237.93+$176.4KVRISX
7$975,561$755,672.36$37,536$5,121.41+$938.0KVRISX
8$7,749,095$6,705,244.31$50,079$8,338.38+$7.70MVRISX
9$107,845,188$99,553,656.17$69,753$14,065.80+$107.78MVRISX
10$2,705,116,788$2,589,722,437.35$102,337$24,771.77+$2705.01MVRISX

VRISX vs ABBV: Complete Analysis 2026

VRISXStock

The investment seeks capital appreciation. Under normal circumstances, the fund invests at least 80% of its assets in equity securities of non-U.S. small- and mid-capitalization companies. The advisor intends to diversify its investments among countries and normally to have represented in the portfolio business activities of a number of different countries. Equity securities in which the fund invests include common stocks, preferred stocks and American Depositary Receipts (ADRs). It is non-diversified.

Full VRISX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VRISX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VRISX vs SCHDVRISX vs JEPIVRISX vs OVRISX vs KOVRISX vs MAINVRISX vs JNJVRISX vs MRKVRISX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.